SCHEMBL207759

SCHEMBL207759

[C]1=CC=Cc2ccccc2N1

nearest known ligand 0.44

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8855 0.68 GAA (0.48) GAAMAPT
SCHEMBL20958405 0.65 GAA (0.50) GAAMAPT
SCHEMBL6198503 0.64 MAPT (0.48) GAAMAPT
SCHEMBL210283 0.64 GAA (0.43) GAAMAPT
SCHEMBL206343 0.64 GAA (0.33) GAAMAPT
SCHEMBL34259 0.64 GAA (0.48) GAAMAPT
Iminostilbene SCHEMBL75288 0.63 MAPT (1.00) GAAMAPT
Iminostilbene SCHEMBL29926907 0.63 MAPT (1.00) GAAMAPT
SCHEMBL8654087 0.62 GAA (0.46) GAAMAPT
Iodide SCHEMBL12466756 0.62 GAA (0.46) GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023016518-A1 HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF 四川海思科制药有限公司 2023-02-16 WO claimed
CN-113861188-A Pyrazolo [3,4-b ] pyridine derivative, preparation method thereof and application thereof as HPK1 inhibitor 杭州医学院 2021-12-31 CN claimed
CN-113105420-A Fused ring arylamine compound, application thereof and organic electroluminescent device containing compound 浙江虹舞科技有限公司 2021-07-13 CN claimed
US-20210198235-A1 DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF AURANSA INC. 2021-07-01 US claimed
WO-2021123883-A1 MACROCYCLIC AMIDES ACTING AS PLASMEPSIN INHBITORS FOR THE TREATMENT OF MALARIA LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2021-06-24 WO claimed
CN-112939788-A Amantadine compound, application thereof and organic electroluminescent device containing amantadine compound 浙江虹舞科技有限公司 2021-06-11 CN claimed
WO-2021001697-A1 NOVEL BORONIC ACID CONTAINING PEPTIDOMIMETICS AS MALARIAL SERINE PROTEASE INHIBITORS LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2021-01-07 WO claimed
WO-2019103897-A1 DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF AURANSA INC. (US) 2019-05-31 WO claimed
US-20180072758-A1 5HT3 RECEPTOR ANTAGONISTS TAKEDA CALIFORNIA, INC. 2018-03-15 US claimed
WO-2017069601-A1 SUBSTITUTED AMINOALKYLAZOLES AS MALARIAL ASPARTIC PROTEASE INHIBITORS LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2017-04-27 WO claimed
EP-0848000-A1 Pharmaceutical pyridine derivatives, processes for preparing the same and intermediates therefor TANABE SEIYAKU CO., LTD. (JP) 1998-06-17 EP claimed
EP-0748805-B1 Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them TANABE SEIYAKU CO (JP) 1998-04-08 EP claimed
WO-1997008155-A1 NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES NOVARTIS AG (CH) 1997-03-06 WO claimed
EP-0748805-A1 Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them TANABE SEIYAKU CO., LTD. (JP) 1996-12-18 EP claimed
CN-1033453-C Pyridylthiazolidine carboxylic acid amide derivative and its preparing method SANKYO CO (JP) 1996-12-04 CN claimed
US-5576321-A ALKOXY-SUBSTITUTED INDOLES ELI LILLY AND COMPANY (US) 1996-11-19 US claimed
WO-1996022290-A1 COMPOUNDS HAVING EFFECTS ON SEROTONIN-RELATED SYSTEMS ELI LILLY AND COMPANY (US) 1996-07-25 WO claimed
EP-0722941-A2 Compounds having effects on serotonin-related systems ELI LILLY AND COMPANY (US) 1996-07-24 EP claimed
CN-1074682-A Pyridylthiazolidine carboxylic acid amide derivatives, their preparation and their therapeutic use SANKYO CO (JP) 1993-07-28 CN claimed
CN-1039810-A ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS SMITHKLINE BECKMAN CORP (US) 1990-02-21 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210198235-A1 DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF THPO, PIR, PAK6 GAA 3618/4885MAPT 2532/4885
US-20180072758-A1 5HT3 RECEPTOR ANTAGONISTS HTR3A, HTR3B, HTR5A GAA 1767/4885MAPT 1056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.